

Medtronic

Success Simplified

Achieve more with tailored AF ablation

Based on a matched-adjusted indirect comparison of the SPHERE Per-AF and ADVANTAGE AF Phase I Trials.[†]

Indirect comparisons are not a substitute for head-to-head trials. Indirect comparisons have potential bias from unmeasured confounding factors, reduced statistical power, and imperfect matching of treatment effect modifiers.

Higher probability of success[†]

77.4%

12-month freedom from atrial arrhythmias in matched cohort of patients treated with the Sphere-9™ catheter (N = 205, p = 0.003).

63.5%

12-month freedom from atrial arrhythmias for patients treated with the FARAPUSLE™* PFA system (N = 260).

Even when adjusted to account for differences in adjunctive linear ablation, results did not significantly change.[‡]



**Sphere-9
catheter**

[†] OR 0.51 (95% CI:0.32-0.80), p = 0.003


[‡] MAIC-adjusted results for the sensitivity analysis performed to account for differences in adjunctive lesion sets: OR 0.44 (95% CI: 0.23-0.86), p = 0.017

Unparalleled versatility

Map, ablate, and validate: from PVI to CTI with a zero exchange workflow.

One Sphere-9 catheter

used in more than 97% of SPHERE Per-AF procedures (N = 206/212).²



All-in-one mapping and ablation

Dual-energy ablation and Close-Unipolar™ mapping with full integration to the Affera™ mapping system

Less fluoro

5.1 ± 7.1min

Sphere-9 catheter in SPHERE Per-AF

19.5 ± 13.1min

FARAPULSE PFA system in ADVANTAGE AF I


74%

less fluoro time on average after matching (p < 0.01)


Up to three catheters

used in ADVANTAGE AF I procedures.

FARAWAVE™* PFA catheter used for PVI and LA posterior wall isolation in all cases.



Additional RF catheter used for CTI line ablation in 19% of patients (N = 50/260).




Supplementary high-density mapping catheter usage was not reported, but 3-D mapping was used in 75% of cases (N = 195/260).

More tailored ablation, uncompromised efficiency

Despite differences in adjunctive lesion sets performed, **skin-to-skin procedure times were similar between groups** after matching for baseline characteristics (p = 0.41, Sphere-9 catheter: 100.3 ± 34.3 min, FARAWAVE catheter: 103 ± 34.8 min)

Strong safety profile

No significant difference in primary safety event rates between patients treated with the Sphere-9 catheter and those treated with the FARAWAVE catheter, 1.8% versus 2.3%, respectively, after matching for baseline characteristics (p = 0.72).



1. Matsumoto K, van Bragt KA, Kueffer FJ, Mburu W, Tarakji KG. Indirect treatment comparison of two pulsed field ablation systems for the treatment of persistent atrial fibrillation. *J Interv Cardio Electrophysiol*. Published online September 10, 2025.
2. Anter E, Mansour M, Nair D, et al. Dual-energy lattice-tip ablation system for persistent atrial fibrillation: a randomized trial. *Nat Med*. August 2024;30(8):2303–2310.

This material should not be considered the exclusive source of information, it does not replace or supersede information contained in the device manual(s). Please note that the intended use of a product may vary depending on geographical approvals. See the device manual(s) for detailed information regarding the intended use, the (implant) procedure, indications, contraindications, warnings, precautions, and potential adverse events. For a MRI compatible device(s), consult the MRI information in the device manual(s) before performing a MRI. If a device is eligible for eIFU usage, instructions for use can be found at Medtronic's website manuals.medtronic.com. Manuals can be viewed using a current version of any major internet browser. For best results, use Adobe Acrobat® Reader with the browser. Medtronic products placed on European markets comply with EU and UK legislation (if applicable) on medical devices. For any further information, contact your local Medtronic representative. Medtronic medical devices marketed in Spain are in compliance with the Spanish legislation in force.

Medtronic

Europe
Medtronic International Trading Sàrl.
Route du Molliau 31
Case postale
CH-1131 Tolochenaz
Tel: +41 (0)21 802 70 00
Fax: +41 (0)21 802 79 00

23249573-en-emea ©2026 Medtronic. Medtronic, Medtronic logo, and Engineering the extraordinary are trademarks of Medtronic. All other brands are trademarks of a Medtronic company.

[medtronic.eu](https://www.medtronic.eu)